{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T06:52:06Z","timestamp":1775890326124,"version":"3.50.1"},"reference-count":63,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,2,20]],"date-time":"2022-02-20T00:00:00Z","timestamp":1645315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Glaucoma is a wide-spread eye disease caused by elevated intraocular pressure. Uncontrolled, this pressure may lead to damages to the optic nerve. Prostaglandin analogues, such as latanoprost and travoprost (which are water-insoluble active substances), are the most used class of active pharmaceutical ingredient. To administer them as eye drops, preservatives, such as benzalkonium chloride, are used as solubilizers. The latter is known to cause a local inflammation when used chronically and is not recommended for patients with ocular surface disorders. In this work, we sought to use polysorbate 80 (PS80) as a solubilizing agent simultaneously with sodium hyaluronate (NaHA) as a thickener and cytoprotective agent for the corneal surface. The first part of this study assessed the compatibility of the excipients with the active substance, using physicochemical methods such as spectra fluorescence and differential scanning calorimetry (DSC), as well as the solubilization mechanism of PS80 regarding prostaglandin analogues using nuclear magnetic resonance (NMR). The second part evaluated the stability of a formula candidate, its viscosity upon instillation, and its pharmacokinetic profile in rabbits as compared to the commercially approved medicine Travatan\u00ae. The results show that sodium hyaluronate is inert with respect to travoprost, while PS80 successfully solubilizes it, meaning that benzalkonium chloride is no longer required. Moreover, the pharmacokinetic profiles of the rabbits showed that the original formula described in the present study enhanced the ocular bioavailability of the drug, making it a promising product to control intraocular pressure with a potential reduced dosage of travoprost, therefore minimizing its related side effects.<\/jats:p>","DOI":"10.3390\/pharmaceutics14020453","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T08:23:29Z","timestamp":1645431809000},"page":"453","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["New Preservative-Free Formulation for the Enhanced Ocular Bioavailability of Prostaglandin Analogues in Glaucoma"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9677-2440","authenticated-orcid":false,"given":"Gabriel","family":"Alviset","sequence":"first","affiliation":[{"name":"Unither D\u00e9veloppement Bordeaux, ZA Tech Espace, av. Toussaint Catros, 33185 Le Haillan, France"},{"name":"Facult\u00e9 de Sant\u00e9 de Paris, CNRS, INSERM, UTCBS, 75006 Paris, France"},{"name":"Assistance Publique H\u00f4pitaux de Paris (AP-HP), Agence G\u00e9n\u00e9rale des \u00c9quipements et Produits de Sant\u00e9 (AGEPS), D\u00e9partement de Recherche et D\u00e9veloppement Pharmaceutique (DRDP), 7 rue du fer \u00e0 Moulin, 75005 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4865-3348","authenticated-orcid":false,"given":"Yohann","family":"Corvis","sequence":"additional","affiliation":[{"name":"Facult\u00e9 de Sant\u00e9 de Paris, CNRS, INSERM, UTCBS, 75006 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Hammad","sequence":"additional","affiliation":[{"name":"Facult\u00e9 de Sant\u00e9 de Paris, CNRS, CiTCoM, 75006 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josiane","family":"Lemut","sequence":"additional","affiliation":[{"name":"CMC Expert, 84 rue Maurice B\u00e9jart, 34080 Montpellier, France"},{"name":"Unither Pharmaceuticals, 3-5 rue St-Georges, 75009 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Maury","sequence":"additional","affiliation":[{"name":"Unither Pharmaceuticals, 3-5 rue St-Georges, 75009 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3323-2997","authenticated-orcid":false,"given":"Nathalie","family":"Mignet","sequence":"additional","affiliation":[{"name":"Facult\u00e9 de Sant\u00e9 de Paris, CNRS, INSERM, UTCBS, 75006 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9811-1520","authenticated-orcid":false,"given":"Vincent","family":"Boudy","sequence":"additional","affiliation":[{"name":"Facult\u00e9 de Sant\u00e9 de Paris, CNRS, INSERM, UTCBS, 75006 Paris, France"},{"name":"Assistance Publique H\u00f4pitaux de Paris (AP-HP), Agence G\u00e9n\u00e9rale des \u00c9quipements et Produits de Sant\u00e9 (AGEPS), D\u00e9partement de Recherche et D\u00e9veloppement Pharmaceutique (DRDP), 7 rue du fer \u00e0 Moulin, 75005 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jcjo.2012.02.003","article-title":"Epidemiology of Glaucoma: What\u2019s New?","volume":"47","author":"Cook","year":"2012","journal-title":"Can. J. Ophthalmol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The Pathophysiology and Treatment of Glaucoma: A Review","volume":"311","author":"Weinreb","year":"2014","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.preteyeres.2004.06.001","article-title":"The Optic Nerve Head as a Biomechanical Structure: A New Paradigm for Understanding the Role of IOP-Related Stress and Strain in the Pathophysiology of Glaucomatous Optic Nerve Head Damage","volume":"24","author":"Burgoyne","year":"2005","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0039-6257(05)80042-6","article-title":"Mechanisms of Optic Nerve Damage in Primary Open Angle Glaucoma","volume":"39","author":"Fechtner","year":"1994","journal-title":"Surv. Ophthalmol."},{"key":"ref_6","first-page":"197","article-title":"Clinical Implications of Pharmacogenetics for Glaucoma Therapeutics","volume":"3","author":"McLaren","year":"2003","journal-title":"Pharm. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.lfs.2019.02.029","article-title":"Glaucoma: Current Treatment and Impact of Advanced Drug Delivery Systems","volume":"221","author":"Yadav","year":"2019","journal-title":"Life Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1345\/aph.1A178","article-title":"Prostaglandin Analog Treatment of Glaucoma and Ocular Hypertension","volume":"36","author":"Alexander","year":"2002","journal-title":"Ann. Pharmacother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jfo.2010.06.018","article-title":"Les conservateurs des collyres: Vers une prise de conscience de leur toxicit\u00e9","volume":"33","author":"Vaede","year":"2010","journal-title":"J. Fr. Ophtalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijpharm.2011.03.006","article-title":"The Stabilization Mechanism of Latanoprost","volume":"410","author":"Ochiai","year":"2011","journal-title":"Int. J. Pharm."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2147\/OPTH.S150816","article-title":"Glaucoma Therapy: Preservative-Free for All?","volume":"12","author":"Thygesen","year":"2018","journal-title":"Clin. Ophthalmol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1120672117753703","article-title":"Effect of Changing from Preserved Prostaglandins to Preservative-Free Tafluprost in Patients with Glaucoma on Tear Film Thickness","volume":"28","author":"Hommer","year":"2018","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"377","DOI":"10.4236\/pp.2013.44054","article-title":"Comparison of Efficacy and Safety Evaluation of Latanoprost Formulations with and without Benzalkonium Chloride","volume":"04","author":"Kasai","year":"2013","journal-title":"Pharmacol. Pharm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/ICO.0b013e31815cf651","article-title":"Comparison of Corneal and Conjunctival Changes After Dosing of Travoprost Preserved With SofZia, Latanoprost With 0.02% Benzalkonium Chloride, and Preservative-Free Artificial Tears","volume":"27","author":"Kahook","year":"2008","journal-title":"Cornea"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jcjo.2016.12.008","article-title":"Normal Tension Glaucoma Management: A Survey of Contemporary Practice","volume":"52","author":"Symes","year":"2017","journal-title":"Can. J. Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/eye.2011.82","article-title":"Novel Drug Delivery Systems for Glaucoma","volume":"25","author":"Lavik","year":"2011","journal-title":"Eye"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.2147\/OPTH.S30261","article-title":"PERSIST: Physician\u2019s Evaluation of Restasis\u00ae Satisfaction in Second Trial of Topical Cyclosporine Ophthalmic Emulsion 0.05% for Dry Eye: A Retrospective Review","volume":"6","author":"Mah","year":"2012","journal-title":"Clin. Ophthalmol."},{"key":"ref_18","unstructured":"Di Napoli, G. (2003). Compositions for Ophtalmic Use Containing Cyclosporin, Hyaluronic Acid and Polysorbate. (No. EP 1 142 566 B1), European Patent."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2147\/OPTH.S40147","article-title":"Safety Comparison of Additives in Antiglaucoma Prostaglandin (PG) Analog Ophthalmic Formulations","volume":"7","author":"Fukuda","year":"2013","journal-title":"Clin. Ophthalmol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1089\/jop.2007.0099","article-title":"An Assessment of the Ocular Safety of Inactive Excipients Following Sub-Tenon Injection in Rabbits","volume":"24","author":"Younis","year":"2008","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jconrel.2020.10.025","article-title":"Therapeutic Nanoemulsions in Ophthalmic Drug Administration: Concept in Formulations and Characterization Techniques for Ocular Drug Delivery","volume":"328","author":"Singh","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_22","first-page":"3409","article-title":"Cytoprotective Effects of Hyaluronic Acid and Carbomer 934P in Ocular Surface Epithelial Cells","volume":"43","author":"Debbasch","year":"2002","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/S0886-3350(02)01540-7","article-title":"Corneal Endothelial Cell Protection during Phacoemulsification: Low- versus High-Molecular-Weight Sodium Hyaluronate","volume":"28","author":"Miyata","year":"2002","journal-title":"J. Cataract Refract. Surg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e6538051","DOI":"10.1155\/2016\/6538051","article-title":"Hyaluronate Acid-Dependent Protection and Enhanced Corneal Wound Healing against Oxidative Damage in Corneal Epithelial Cells","volume":"2016","author":"Zhong","year":"2016","journal-title":"J. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.exer.2011.10.017","article-title":"Effect of Prostaglandin Analogues on Tear Proteomics and Expression of Cytokines and Matrix Metalloproteinases in the Conjunctiva and Cornea","volume":"94","author":"Kim","year":"2012","journal-title":"Exp. Eye Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1021\/la00063a015","article-title":"Fluorescence Probes for Critical Micelle Concentration Determination","volume":"1","author":"Goddard","year":"1985","journal-title":"Langmuir"},{"key":"ref_27","unstructured":"Reda, H.S. (2014). Ophthalmic Compositions Comprising Prostaglandin F2 Alpha Derivatives and Hyaluronic Acid. (No. US20140228364A1), U.S. Patent."},{"key":"ref_28","unstructured":"(2018). United States Pharmacopeial Convention Travoprost Ophthalmic Solution\u2014Monograph. The United States Pharmacopeia 41, The National Formulary 36, USP."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Kotreka, U.K., Davis, V.L., and Adeyeye, M.C. (2017). Development of Topical Ophthalmic In Situ Gel-Forming Estradiol Delivery System Intended for the Prevention of Age-Related Cataracts. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0172306"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"118734","DOI":"10.1016\/j.ijpharm.2019.118734","article-title":"Novel in Situ Gelling Ophthalmic Drug Delivery System Based on Gellan Gum and Hydroxyethylcellulose: Innovative Rheological Characterization, in Vitro and in Vivo Evidence of a Sustained Precorneal Retention Time","volume":"574","author":"Destruel","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"192","DOI":"10.4103\/2231-4040.85540","article-title":"Reduction in Drop Size of Ophthalmic Topical Drop Preparations and the Impact of Treatment","volume":"2","author":"Kumar","year":"2011","journal-title":"J. Adv. Pharm. Technol. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0928-0987(99)00051-2","article-title":"Rheological Studies of the Gelation of Deacetylated Gellan Gum (Gelrite) in Physiological Conditions","volume":"9","author":"Paulsson","year":"1999","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0141-7037(93)80023-7","article-title":"The Composition and Interfacial Properties of Tears, Tear Substitutes and Tear Models","volume":"16","author":"Bright","year":"1993","journal-title":"J. Br. Contact Lens Assoc."},{"key":"ref_34","first-page":"377","article-title":"Methods for the Study of Irritation and Toxicity of Substances Applied Topically to the Skin and Mucous Membranes","volume":"82","author":"Draize","year":"1944","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_35","first-page":"1","article-title":"Review of a technic for the estimation of area under the concentration curve in pharmacokinetic analysis","volume":"48","author":"Bourget","year":"1993","journal-title":"Therapie"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1021\/mp100445k","article-title":"Interaction between Drug Loaded Polyaspartamide-Polylactide-Polysorbate Based Micelles and Cell Membrane Models: A Calorimetric Study","volume":"8","author":"Sarpietro","year":"2011","journal-title":"Mol. Pharm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1002\/jps.22727","article-title":"Physicochemical Stability of Solid Dispersions of Enantiomeric or Racemic Ibuprofen in Stearic Acid","volume":"100","author":"Corvis","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1021\/acsabm.9b00598","article-title":"Therapeutic Role of Deep Eutectic Solvents Based on Menthol and Saturated Fatty Acids on Wound Healing","volume":"2","author":"Silva","year":"2019","journal-title":"ACS Appl. Bio Mater."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/etc.5620171002","article-title":"Sorption Coefficients of Polycyclic Aromatic Hydrocarbons for Two Lake Sediments: Influence of the Bactericide Sodium Azide","volume":"17","author":"Sinnige","year":"1998","journal-title":"Environ. Toxicol. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1007\/s10973-019-08223-7","article-title":"DSC Supported by Factor Analysis as a Reliable Tool for Compatibility Study in Pharmaceutical Mixtures","volume":"138","author":"Rojek","year":"2019","journal-title":"J. Therm. Anal. Calorim."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s10973-015-5077-z","article-title":"Compatibility Study between Atorvastatin and Excipients Using DSC and FTIR","volume":"123","author":"Pereira","year":"2016","journal-title":"J. Therm. Anal. Calorim."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10973-011-1299-x","article-title":"Application of DSC, IST, and FTIR Study in the Compatibility Testing of Nateglinide with Different Pharmaceutical Excipients","volume":"108","author":"Pani","year":"2011","journal-title":"J. Therm. Anal. Calorim."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11743-000-0113-4","article-title":"On the Measurement of Critical Micelle Concentrations of Pure and Technical-Grade Nonionic Surfactants","volume":"3","author":"Patist","year":"2000","journal-title":"J. Surfact. Deterg."},{"key":"ref_44","first-page":"1","article-title":"Effect of Temperature Changes on Critical Micelle Concentration for Tween Series Surfactant","volume":"13","author":"Mahmood","year":"2013","journal-title":"Glob. J. Sci. Front. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s13197-015-2009-7","article-title":"Effect of Plasticizer Type and Concentration on Physical Properties of Biodegradable Films Based on Sugar Palm (Arenga Pinnata) Starch for Food Packaging","volume":"53","author":"Sanyang","year":"2016","journal-title":"J. Food Sci. Technol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.1021\/jp071101n","article-title":"A Calorimetry and Light Scattering Study of the Formation and Shape Transition of Mixed Micelles of EO20PO68EO20 Triblock Copolymer (P123) and Nonionic Surfactant (C12EO6)","volume":"111","author":"Niemiec","year":"2007","journal-title":"J. Phys. Chem. B"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/jps.2600630136","article-title":"CMC of Polysorbates","volume":"63","author":"Wan","year":"1974","journal-title":"J. Pharm. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejpb.2015.04.032","article-title":"New Prostaglandin Analog Formulation for Glaucoma Treatment Containing Cyclodextrins for Improved Stability, Solubility and Ocular Tolerance","volume":"95","author":"Guinchard","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_49","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (2003). Q1A(R2) Stability Testing Of New Drug Substances And Products. ICH Harmonised Tripartie Guidelines, Brill|Nijhoff."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1021\/j100721a006","article-title":"Viscosity of Water at Various Temperatures","volume":"73","author":"Korson","year":"1969","journal-title":"J. Phys. Chem."},{"key":"ref_51","first-page":"4641","article-title":"Effect of Viscosity, Surface Tension and Mucoadhesion on Ocular Residence Time of Lubricant Eye Drops","volume":"50","author":"Doshi","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/OPX.0b013e3181824dc4","article-title":"Effect of Viscosity on Tear Drainage and Ocular Residence Time","volume":"85","author":"Zhu","year":"2008","journal-title":"Optom. Vis. Sci."},{"key":"ref_53","first-page":"12","article-title":"An in Vitro Method Simulating Drug Release from Viscous Eye Drops in Rabbit and Man","volume":"31","year":"1979","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","article-title":"Ocular Drug Delivery","volume":"12","author":"Gaudana","year":"2010","journal-title":"AAPS J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1089\/jop.2012.0241","article-title":"Anterior Eye Segment Drug Delivery Systems: Current Treatments and Future Challenges","volume":"29","author":"Molokhia","year":"2013","journal-title":"J. Ocul. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Destruel, P.-L., Zeng, N., Brignole-Baudouin, F., Douat, S., Seguin, J., Olivier, E., Dutot, M., Rat, P., Dufa\u00ff, S., and Dufa\u00ff-Wojcicki, A. (2020). In Situ Gelling Ophthalmic Drug Delivery System for the Optimization of Diagnostic and Preoperative Mydriasis: In Vitro Drug Release, Cytotoxicity and Mydriasis Pharmacodynamics. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12040360"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.addr.2017.12.017","article-title":"Ophthalmic Gels: Past, Present and Future","volume":"126","author":"Zidan","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0304-4165(98)00155-X","article-title":"Hyaluronate-Alginate Combination for the Preparation of New Biomaterials: Investigation of the Behaviour in Aqueous Solutions","volume":"1426","author":"Oerther","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"194906","DOI":"10.1063\/1.2387948","article-title":"Shear Thinning in Dilute Polymer Solutions","volume":"125","author":"Ryder","year":"2006","journal-title":"J. Chem. Phys."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1091581809337738","article-title":"Final Report of the Safety Assessment of Hyaluronic Acid, Potassium Hyaluronate, and Sodium Hyaluronate","volume":"28","author":"Becker","year":"2009","journal-title":"Int. J. Toxicol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"119402","DOI":"10.1016\/j.ijpharm.2020.119402","article-title":"Nanoemulsion as a Feasible and Biocompatible Carrier for Ocular Delivery of Travoprost: Improved Pharmacokinetic\/Pharmacodynamic Properties","volume":"583","author":"Ismail","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1111\/j.1523-1755.2005.00352.x","article-title":"AUC-Guided Dosing of Tacrolimus Prevents Progressive Systemic Overexposure in Renal Transplant Recipients","volume":"67","author":"Scholten","year":"2005","journal-title":"Kidney Int."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2165\/00003088-199733030-00002","article-title":"Clinical Pharmacokinetics and Dose Optimisation of Carboplatin","volume":"33","author":"Duffull","year":"1997","journal-title":"Clin. Pharmacokinet."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/2\/453\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:23:35Z","timestamp":1760135015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/2\/453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,20]]},"references-count":63,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["pharmaceutics14020453"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14020453","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,20]]}}}